Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Seattle Children's leukemia patient has positive response to T-cell therapy

Seattle Children's leukemia patient has positive response to T-cell therapy

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Advanced genetics technologies may help predict patient outcomes in people with ALL

Advanced genetics technologies may help predict patient outcomes in people with ALL

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Cancer immunotherapies promise to be a new tool in fight against cancer

Cancer immunotherapies promise to be a new tool in fight against cancer

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

Study: African Americans with CLL have shorter survival times than Caucasians

Study: African Americans with CLL have shorter survival times than Caucasians

Epigenome mapping uncovers unique patterns that emerge during generation of brain circuitry

Epigenome mapping uncovers unique patterns that emerge during generation of brain circuitry

Findings uncover epigenomic modification that occurs during brain formation

Findings uncover epigenomic modification that occurs during brain formation

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

Study shows miR-22 plays a key role in breast and blood cancers

Study shows miR-22 plays a key role in breast and blood cancers

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Weekend reading: Chemo revolution, Lyme disease confusion and the residency mismatch

Weekend reading: Chemo revolution, Lyme disease confusion and the residency mismatch

UNIGE researchers identify genomic variations associated with trisomy 21

UNIGE researchers identify genomic variations associated with trisomy 21

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Eisai submits BELVIQ NDS with Health Canada

Eisai submits BELVIQ NDS with Health Canada

New study provides guidelines for stem cell transplantation in older MDS patients

New study provides guidelines for stem cell transplantation in older MDS patients

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.